A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521108-23-00

Enrollment

165

Registered

2026-04-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

Annualized rate of moderate/severe exacerbations.

Detailed description

Time to first moderate/severe exacerbation., Change from baseline in SGRQ total score (measured using the SGRQ-C) at Week 52., Change from baseline in E-RS: COPD total score at Week 52.

Interventions

DRUGNovolizer Salbutamol 100 microgrammes/dose

DRUGpoudre pour inhalation

DRUGSterile 0.9% (w/v) sodium chloride solution in single-use PFS

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Annualized rate of moderate/severe exacerbations.	—

Secondary

Measure	Time frame
Time to first moderate/severe exacerbation., Change from baseline in SGRQ total score (measured using the SGRQ-C) at Week 52., Change from baseline in E-RS: COPD total score at Week 52.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 9, 2026